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ABSTRACT
Pfannenstiel, Keith B. Effects of Resistance Exercise Training on DoxorubicinInduced Cardiotoxicity. Published Doctor of Philosophy Dissertation,
University of Northern Colorado, 2015.

In recent decades cancer survivorship has steadily increased; however,
the adverse side effects associated with chemotherapy treatment can diminish
a patient’s overall quality of life. One of the most effective and widely used
chemotherapeutic agents is doxorubicin (DOX). Though highly effective, its
use is limited by a dose-dependent cardiotoxicity. While it is known that
exercise preconditioning with endurance training models provide a
cardioprotective effect to DOX treatment, little focus has been placed on the
effects of a resistance training (RT) model on DOX-induced cardiac
dysfunction.
The purpose of the study was to determine the effects of a 12-week RT
model on DOX-induced cardiac dysfunction to determine if any
cardioprotective effects are a result of a reduction in lipid peroxidation and to
determine if any cardioprotective effects are a result of a preservation of the
cardiac myosin heavy chain (MHC) isoform distribution.
Ten-week-old male Sprague-Dawley rats were randomly selected to
undergo 12 weeks of RT or remain sedentary (SED). Twenty-four hours
following the completion of the exercise training or sedentary period, animals
iii

received a 12.5 mg/kg bolus intraperitoneal injection of DOX or a bolus
intraperitoneal injection of 0.9% saline. Five days following injection, animals
were sacrificed. Cardiac function was assessed both in vivo and ex vivo and
the left ventricle tissue was used to assess lipid peroxidation, as measured by
malondialdehyde (MDA) + 4-hydroxyalkenal (HAE) and percentage of β-MHC.
The DOX treatment induced cardiac dysfunction when measured both
in vivo and ex vivo. The RT provided a cardioprotective effect, evident by
significant increases in end systolic pressure, left ventricular developed
pressure, and the maximal rate of developed pressure. No significant
difference existed between RT+DOX and SED+DOX in lipid peroxidation;
however, RT did attenuate the α- to β-MHC shift that occurs with DOX
treatment.
These data suggest that 12 weeks of the RT model used provided
cardioprotection against DOX-induced cardiac dysfunction and may be a result
of preservation of the cardiac MHC isoform distribution.
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CHAPTER I

INTRODUCTION

Cancer is one of the leading causes of morbidity and mortality
throughout the world. In 2015, it is estimated that there will be more than 1.6
million new cases of cancer diagnosed in the United States (Siegel, Miller, &
Jemal, 2015). In addition, it is estimated that more than 580,000 people are
expected to succumb to the disease in 2015, thus statistically making cancer
the second most common cause of death in the United States. The risk of
dying from cancer has steadily declined over the past two decades, including a
22% decrease between 1991 and 2011 (Siegel et al., 2015). Increased
survival rates for cancer patients are due, in part, to progressive methods of
prevention, detection, and treatment options available to patients. Increased
survival rates have led to a greater emphasis on improving overall quality of
life in cancer survivors, with a particular focus on reducing or attenuating
treatment-related side effects.
A Food and Drug Administration approved chemotherapeutic agent
successful in the treatment of a variety of cancers is doxorubicin (DOX),
clinically known as Adriamycin®. Clinicians began prescribing DOX to cancer
patients as a chemotherapy treatment in 1974. Since then, it has been used
to treat a variety of malignancies, both solid and hematological (Weiss, 1992).
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While substantially effective at treating cancer, the implementation of DOX into
routine cancer treatment regimens has been limited due to its known
detrimental cardiotoxicity. A well-characterized side effect of DOX is its dosedependent cardiotoxicity, which can be manifested as cardiac dysrhythmias,
contractile dysfunction, or even congestive heart failure (Steinherz, Steinherz,
Tan, Heller, & Murphy, 1991). Mechanistic actions of DOX that have been
reported to induce cardiotoxicity include interference with deoxyribonucleic
acid (DNA) strand separation during replication (Bachur et al., 1992), induction
of apoptosis (Wonders, Hydock, Greufe, Schneider, & Hayward, 2009), and
excess generation of reactive oxygen species (ROS) (Minotti, Menna,
Salvatorelli, Cairo, & Gianni, 2004)
Aside from examining ways to prevent, diagnose, and treat cancer,
researchers have diligently investigated interventions aimed at the reduction or
attenuation of burdensome side effects commonly accompanying cancer
treatment. Purported to counteract many of the transient and chronic effects
associated with cancer treatments, the role of regular exercise in the
prevention and treatment of cancer has been the focus of much clinical
research over the past 15 years.
Studies have suggested that exercise preconditioning may reduce
DOX-induced cardiotoxicity following treatment (Hydock, Lien, Jensen,
Schneider, & Hayward, 2011; Hydock, Lien, Schneider, & Hayward, 2008;
Jensen, Lien, Hydock, Schneider, & Hayward, 2013). However, not fully
understood are the mechanisms involved with the induction of exercisemediated cardioprotection. Exercise-induced cardioprotection against DOX
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toxicity may be explained by upregulation of heat shock proteins (HSP)
(Chicco, Schneider, & Hayward, 2005), downregulation of pro-apoptotic
pathways (Wonders et al., 2009), increased antioxidant enzymes (Ascensão et
al., 2005; Ashrafi, Roshan, & Mahjoub, 2012; Chicco, Hydock, Schneider, &
Hayward, 2006; Kanter, Hamlin, Unverferth, Davis, & Merola, 1985),
decreased lipid peroxidation (Marques-Alexio et al., 2014; Wonders, Hydock,
Schneider, & Hayward, 2008), decreased cardiac DOX accumulation (Jensen
et al., 2013), and/or by increasing the expression of multi-drug resistance
protein (Krause et al., 2007).
Although a substantial amount of research has focused on the effects of
endurance training, little attention has been placed on the effects of resistance
training (RT) on DOX-induced cardiotoxicity. Cancer rehabilitation programs
have begun to incorporate RT due to the fact that this type of training can
result in significant improvements in muscular strength, aerobic capacity, and
quality of life (Schwartz & Winters-Stone, 2009; Segal et al., 2003; WintersStone et al., 2012). Additionally, RT has been utilized as a rehabilitative
therapy for heart failure, which may accompany DOX treatment, to counteract
damaging peripheral side effects and improve quality of life (Alves, Nunes,
Stefani, & Dal Lago, 2014). To our knowledge, no studies have been
conducted which examine the effects of RT on DOX-induced cardiotoxicity.
Statement of Purpose
The purpose of this study was threefold: (a) to examine the effects of
chronic RT prior to the administration of DOX on in vivo and ex vivo cardiac
function in male Sprague Dawley rats, (b) to determine if any cardioprotective
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effects are a result of a reduction in lipid peroxidation, and (c) to determine if
any cardioprotective effects are a result of a preservation of the cardiac
myosin heavy chain (MHC) isoform distribution.
Research Hypotheses
H1

Resistance training will provide protection against the cardiac
dysfunction associated with doxorubicin treatment.

H2

Resistance training will mitigate the increase in cardiac lipid
peroxidation associated with doxorubicin treatment.

H3

Resistance training will attenuate the cardiac α- to β-myosin
heavy chain shift that occurs with doxorubicin treatment.
Abbreviations

Table 1.1 shows the abbreviations used in this study.
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Table 1.1
Abbreviations Used in This Study
Abbreviation

Explanation

Abbreviation

Explanation

4-HAE

4-hydroxyalkenal

MDA

malondialdehyde

4-HNE

4-hydroxynonenal

MHC

myosin heavy chain

ATP

adenosine triphosphate

MnSOD

manganese superoxide
dismutase

MPTP

mitochondrial permeability
transitional pore

NADH

nicotinamide adenine
dinucleotide

NO

nitric oxide

O2

oxygen

2+

CA

calcium

CAT

catalase

CHF

chronic heart failure

CuSOD

copper zinc superoxide
dismulase

DNA

deoxyribonucleic acid

DOX

doxorubicin

+dP/dt

maximum rate of
developed pressure

-dP/dt

minimum rate of
developed pressure

-

O2•

superoxide anion

OH

hydroxyl radical

ONOO-

peroxynitrite

PWd

posterior wall thickness
during diastole

PWs

posterior wall thickness
during systole

RNS

reactive nitrogen species

ROS

reactive oxygen species

RYR

ryanodine receptor

SERCA2

sarcoendoplasmic
reticulum ATPase 2

EDP

end diastolic pressure

EF

ejection fraction

ESP

end systolic pressure

FS

fractional shortening

GPX

glutathione peroxidase

HSP

heat shock protein

H2O2

hydrogen peroxide

i.p.

intraperitoneal

SED

sedentary

LV

left ventricular

SOD

superoxide dismutase

LVDd

LV end diastolic
diameter

SWd

septal wall thickness
during diastole

LVDP

LV developed pressure

SWs

LVDPd

LVDP during diastole

septal wall thickness
during systole

LVDs

LV end systolic
diameter
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Definition of Terms
Apoptosis. Programmed cell death.
Cardiomyopathy. Disease of the heart when the myocardium becomes
enlarged, thick, or rigid and can lead to heart failure.
Cardioprotection. Adaptations in the heart that provide increased
tolerance to ischem or chemical-induced injury.
Cardiotoxocity. Damage to the heart from cytotoxic drugs.
Cytochrome c. A small essential protein located at outside of inner
mitochondria membrane attaching to cardiolipin, transports electrons (between
complex III and IV) during aerobic energy production, and initiates intrinsic
apoptosis pathway.
Dilated cardiomyopathy. A pathological condition of the heart where
the chamber enlarges and the walls thin, interfering with ejection of blood from
the heart.
Doxorubicin. Chemotherapy agent approved by the Food and Drug
Administration for the treatment of a variety of cancers including nonHodgkin’s lymphoma, acute leukemia, and multiple myeloma and cancers of
the breast, adrenal cortex, endometrium, lung, and ovary.
Echocardiogram. An ultrasonic technique used to image real-time
cardiac tissue dimensions and blood flow velocities.
M-mode. An imagining mode used to determine cardiac geometry
during echocardiography.
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CHAPTER II

REVIEW OF LITERATURE

Doxorubicin
In 1958, Streptomycin peucetius was isolated from soil by the Farmitalia
Research Laboratory in southern Italy. From Streptomycin peucetius,
researchers were ultimately able to derive doxorubicin (DOX) (Di Marco et al.,
1964). The DOX, trade name Adriamycin®, is a 14-hydroxy analog of
daunorubicin. The DOX is a member of the family of anthracyclines that has
been established as a highly effective antineoplastic agent administered as a
treatment for multiple cancers. These antineoplastic agents are clinically
prescribed to treat leukemia, non-Hodgkin lymphomas, breast cancer,
Hodgkin's disease, and sarcomas (Young, Ozols, & Myers, 1981). Although
effective, DOX is oftentimes accompanied by a number of deleterious side
effects on cardiac tissue, which may include arrhythmias, contractile
abnormalities, dilated cardiomyopathy, and chronic heart failure (Narula et al.,
1996; Singal, Li, Kumar, Danelisen, & Iliskovic, 2000; Zhang, Shi, Li, & Wei,
2009). The mechanisms underlying the toxic effects of DOX still remain
unclear; however, proposed actions include its interference with
topoisomerase-II (Tewey, Chen, Nelson, & Liu, 1984), induction of apoptosis,
and an increased generation of ROS (Minotti et al., 2004).
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The DOX can intercalate DNA leading to the inhibition of
topoisomerase-II by stabilizing the DNA-topoisomerase-II complex. Under
normal conditions, topoisomerase-II is able to cleave the DNA double helix,
thereby allowing DNA fragments to pass through the break before rejoining the
two strands. The formation of the ternary topoisomerase-II-DOX-DNA
cleavage complex inhibits the function of topoisomerase-IIβ (Lyu et al., 2007).
Topoisomerase-IIβ inhibition leads to DNA strand breakage and ultimately
cellular apoptosis (Hilmer, Cogger, Muller, & Le Couteur, 2004; Zhang et al.,
2012). The DOX can also induce cell death by activation of two apoptotic
pathways, extrinsic and intrinsic.
The extrinsic and intrinsic pathways are the two main pathways that
stimulate the caspases. Activated when extracellular signals bind with
transmembrane death receptors, such as the tumor necrosis factor, the
extrinsic pathway can lead to apoptosis beginning with the activation of
caspase-8 (Tait & Green, 2010). The intrinsic pathway begins through the
release of mitochondrial cytochrome c. After release of cytochrome c into the
cytosol, it forms an apoptosome complex by combining with apoptosis
activating factor and procaspase-9. This formation, in turn, leads to the
activation of caspase-9. Caspase-9 cleaves downstream caspases, thereby
initiating apoptosis (Acehan et al., 2002; Salvesen & Dixit, 1997).
Another proposed mechanism of DOX’s antineoplastic effects is
oxidative stress. Normal cells generate a modicum of ROS, which may play a
positive role in the regulation of cell growth and intercellular signaling
(Mantovani et al., 2003). In order to combat the overproduction of ROS, cells

9
produce antioxidant enzymes that can control the concentration of free
radicals to mitigate ROS-mediated damage. These enzymes include
superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase
(GPX). In a physiological milieu, the administration of DOX has been reported
to generate a significant increase in the production of ROS (Balanehru &
Nagarajan, 1992). The condition of an imbalance between the antioxidant and
pro-oxidant forces within and outside the cell is referred to as oxidative stress.
This imbalance may lead to the damage of proteins, DNA, and lipids
(Nordberg & Arnér, 2001).
A common form of a ROS-induced damage is lipid peroxidation (Hrelia
et al., 2002; Tam et al., 2006). The ROS attack and degrade polyunsaturated
fatty acids leading to damage of the membrane structure which, in turn,
compromises membrane integrity. This cascade of events is referred to as
lipid peroxidation. Compromised membrane integrity can alter membrane
receptor function, calcium homeostasis, and eventually induce apoptosis.
Doxorubicin-Induced Cardiotoxicity
The DOX-induced cardiotoxicity is multifactorial and complex, involving
both ultrastructural and functional changes. Evidence indicates that the risk of
cardiotoxicity rises with an increase in the cumulative dose of DOX (Shapiro et
al., 1998; Von Hoff et al., 1979). The DOX-induced cardiotoxicity can be
broken down into three distinct categories: acute myocardial injury, chronic
cardiotoxicity, and late-onset cardiac dysfunction. Occurring immediately
following a single dose of DOX, acute myocardial injury has been observed in
the forms of hypotension, tachycardia, and arrhythmias (Herman, Mhatre, Lee,
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Vick, & Waravdeker, 1971; Schimmel, Richel, van den Brink, & Guchelaar,
2004). The second type of DOX-induced cardiotoxicity, chronic cardiotoxicity,
has been reported to be an established, clinically prevalent form on which
great importance has been placed. Chronic cardiotoxicity is characterized by
tachycardia, left ventricular (LV) cavity dilation, exercise intolerance, and
progressive cardiac injury (Ferrans, 1978). Increased awareness has been
made regarding the third category of DOX-induced cardiotoxicity, late-onset
cardiac dysfunction. Late-onset cardiac dysfunction becomes evident in the
years to decades after treatment with DOX. Key features of late-onset cardiac
dysfunction include arrhythmias, LV systolic dysfunction, cardiomyocyte
damage, and chronic heart failure (Schwartz et al., 1987; Steinherz et al.,
1991). The dose-related significance of chronic and late-onset cardiotoxicity
relating directly to increased mortality rates indicates that if a patient is given a
cumulative dose in excess of 550 mg/m2 of body surface, morbidity rates
dramatically increase (Singal & Iliskovic, 1998).
The heart is a high-energy organ reliant upon a constant supply of
adenosine triphosphate (ATP) via mitochondrial oxidative phosphorylation.
The targeted organelle by DOX-induced cardiotoxicity is the cardiomyocyte
mitochondria. Studies have demonstrated that DOX can accumulate in the
mitochondria, and this may be due to the high affinity DOX has for the
mitochondrial phospholipid cardiolipin (Goormaghtigh, Chatelain, Caspers, &
Ruysschaert, 1980). Cardiolipin is a phospholipid specific to the inner
mitochondrial membrane and plays an integral part in electron transport chain
assembly. The attachment of DOX to cardiolipin creates a complex displacing
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cardiolipin from key mitochondrial proteins. This DOX-cardiolipin complex
inhibits cytochrome c oxidase and mitochondrial enzymatic complex I and III,
reducing ATP production and triggering apoptotic pathways (Goormaghtigh et
al., 1980; Goormaghtigh, Huart, Praet, Brasseur, & Ruysschaert, 1990).
A central mechanism associated with DOX-induced cardiotoxicity is the
overproduction of ROS and reactive nitrogen species (RNS). As stated
previously, cardiomyocytes are highly aerobic and require a constant supply of
ATP by oxidation phosphorylation. The DOX administration may lead to an
overproduction of ROS and RNS, which leads to cardiotoxicity by the
disruption of the cardiac sarcoplasmic reticulum and the mitochondrial
respiratory chain. The increased generation of ROS results mainly in the
mitochondria where it undergoes redox cycling at complex I of the electron
transport chain (Marcillat, Zhang, & Davies, 1989).
The quinone form of DOX can be converted to a semiquinone free
radical through univalent reduction. The semiquinone radical can then be reoxidized by a one-electron transfer to molecular oxygen, regenerating the
parent quinone with superoxide anion (O2•-) as a byproduct (Nohl, Gille, &
Staniek, 1998). Large amounts of O2•- will be generated through redox cycling
between the quinone and semiquinone forms of DOX. The DOX-induced
redox imbalance may lead to the excess generation of superoxide.
The superoxide radical can be converted to hydrogen peroxide (H2O2)
by SOD. From here, the anti-oxidative enzymes, CAT and GPX, reduce H2O2
to water (H2O) (Harrison et al., 2005). The overproduction of O2•- can lead to
increased production of H2O2. The two radicals can react with one another,
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forming a hydroxyl radical (OH), via the Harber-Weiss reaction. This reaction
can lead to lipid peroxidation (Radi, Beckman, Bush, & Freeman, 1991). The
H2O2 is able to traverse the mitochondrial membrane and generate an OH in
the presence of iron, copper, cobalt, and chromium via the Fenton reaction
(Henkler, Brinkmann, & Luch, 2010).
Ferritin is the main iron storage protein. Release of iron from ferritin
can occur in the presence of O2•-. It achieves this dissociation by
disassembling the 4Fe-4S cluster. In doing so, this phenomenon has been
reported to increase the activity of iron regulating protein-1, leading to
increased iron uptake. The increases in free iron at the cellular level can react
with H2O2, which is known as the Fenton reaction, forming an OH (Corna,
Galy, Hentze, & Cairo, 2006).
The DOX can also induce the generation of RNS, such as nitric oxide
(NO) and peroxynitrite (ONOO−). The ONOO−, which is formed from NO and
O2•-, is a highly reactive radical, capable of damaging tissues and cells
(Mccord, 1985). The ONOO− also damages DNA by several mechanisms,
such as single-strand breaks, leading to additional stress on the
cardiovascular system (Szabó & Ohshima, 1997).
Oxidative stress can also disrupt calcium homeostasis by impairing the
ryanodine receptor (RYR) and sarcoendoplasmic reticulum ATPase 2
(SERCA2). The ROS promotes an open state of the RYR and a diminished
effect of SERCA2. This will cause a rise in intracellular calcium (Ca2+) and, in
turn, may induce mitochondrial Ca2+ overload (Kim et al., 2006). Mitochondrial
Ca2+ overload triggers a mitochondrial permeability transition, which leads to
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additional rise in calcium levels by altering the accessibility of mitochondria
permeability transition pores (MPTP). The Ca2+ overload may induce swelling
of the mitochondria, rupturing of the outer mitochondrial membrane, resulting
in the release of cytochrome c into the cytosol (Childs, Phaneuf, Dirks, Phillips,
& Leeuwenburgh, 2002). Release of cytochrome c will lead to the formation of
an apoptosome complex which eventually leads to apoptosis (Sokolove &
Shinaberry, 1988). Oxidative stress can also alter the permeability of MPTP
through the downregulation of anti-apoptotic proteins, such as B-cell
lymphoma 2 and activation of pro-apoptotic proteins, Bcl-2-like protein 4, and
Bcl-2 homologous antagonist/killer (Crompton, 1999).
Doxorubicin-Induced Cardiac Dysfunction
Diminished LV function may be observed within the first six months
after DOX treatment (Ali, Ewer, Gibbs, Swafford, & Graff, 1994). Cardiac
function may be assessed in vivo and ex vivo. In vivo cardiac function can be
analyzed by echocardiography, which assesses left ventricular end diastolic
(LVDd) and end systolic diameter (LVDs), posterior wall thickness during
diastole (PWd) and systole (PWs), septal wall thickness during diastole (SWd)
and systole (SWs), and fractional shortening (FS). Ex vivo function can be
analyzed using an isolated working heart. Measurements obtained from an
isolated working-heart model include left ventricular developed pressure
(LVDP), maximum rate of developed pressure (+dP/dt), minimum rate of
developed pressure (-dP/dt), end systolic pressure (ESP), and end diastolic
pressure (EDP).
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Studies suggest that acute DOX treatment causes cardiac dysfunction
(Chicco et al., 2006; Wonders et al., 2008). In a study by Wonders et al.
(2008) it was found that DOX caused significant reductions in LVDP, ESP, and
+dP/dt five days after a single bolus injection of 15 mg/kg. The DOX treatment
also led to significant increases in EDP and +dP/dt. Cardiac dysfunction has
also been noticeable with smaller acute doses of DOX (Hydock et al., 2008).
Hydock et al. (2008) reported significant in vivo and ex vivo cardiac
dysfunction 5 and 10 days following single bolus injections of DOX at 10
mg/kg. In vivo assessment indicated a significant depression of FS and
significant decreases in SWs and SWd at both time points. Ex vivo
assessment showed that following treatment, LVDP and +dP/dt were
significantly reduced at both time points. Along with this, significant reductions
in –dP/dt were also observed 10 days post injection.
Along with acute DOX treatment, studies have also examined altering
the time course of treatment and cardiac function (Hayward & Hydock, 2007;
Hydock et al., 2011). A cornerstone study was carried out by Hayward and
Hydock (2007) in which they examined in vivo cardiac function for acute and
chronic dosing schedules. Animals received 10 mg/kg of DOX by a bolus
injection (group 1), 10 daily injections of 1 mg/kg/day (group 2), or five weekly
injections of 2 mg/kg/wk (group 3). Cardiac dysfunction was evident within the
acute and chronic dosing groups. Evidence of dysfunction appeared for all
groups in the form of decreased FS. Morphological changes resembling
dilated cardiomyopathy were reported for all three groups. Decreases in
septal and posterior ventricular wall thicknesses were observed in the three
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groups. However, for groups 2 and 3 there was a delayed response in
changes of cardiac geometry.
Exercise Protection
It is widely acknowledged that chronic exercise training provides wideranging benefits to a multitude of organs including the heart. Studies have
reported that different forms of exercise, such as treadmill running, wheelrunning, and swimming can attenuate DOX-induced cardiotoxicity.
Mechanisms underlying the cardioprotection afforded by exercise may be
dependent upon a number of factors including the dose of DOX, the modality
of exercise, the temporal relationship between exercise and DOX treatment,
subject comorbidities, gender, or even accompanying cancer therapies.
Proposed mechanisms of cardioprotection have included reduced DOX
accumulation within the cardiomyocyte (Jensen et al., 2013), attenuating
unfavorable shifts towards β-myosin heavy chain (β-MHC) (Hydock et al.,
2008), decreased oxidative stress (Ascensão et al., 2005), and increased HSP
expression (Ascensão, Ferreira, Oliveira, & Magalhães, 2006; Kavazis,
Smuder, Min, Tümer, & Powers, 2010). From available evidence, it appears
that multiple mechanisms may be simultaneously involved with the protective
effects of chronic aerobic exercise.
Oxidative Stress
One of the main mechanisms for cardiotoxicity is the overproduction of
ROS, which can lead to DNA damage and/or lipid peroxidation. Various
studies have presented results suggestive of exercise as a positive modulator
of oxidative stress, which can be examined by the expression of key

16
antioxidant enzymes (Lennon et al., 2004; Somani, Frank, & Rybak, 1995) and
one of the principle byproducts of lipid peroxidation, malondialdehyde (MDA)
(Marques-Aleixo et al., 2014).
An early study by Quintanilha (1984) was one of the first to report an
increase in antioxidant enzyme activity due to exercise training, and since then
literature on the subject has expanded. A study by Powers et al. (1993) was
the first to examine the influence of intensity and duration of exercise training
on the activity antioxidant enzymes. Animals treadmill trained at one of the
combinations of duration (30, 60, or 90 minutes) and intensity (low, moderate,
or high) for 10 weeks. Intensity was characterized as low (55% of maximal O2
uptake), moderate (65% of maximal O2 uptake), and high (75% of maximal O2
uptake). Results indicated that high intensity exercise for all durations resulted
in an increase SOD activity within the LV. An increase in SOD activity was
also observed in both low and moderate intensity when training was 60
minutes or greater.
Along with these studies, an extensive amount of research has been
conducted examining exercise-induced adaptations in antioxidant activity,
which is believed to play a role in the attenuation or reduction of DOX-induced
cardiotoxicity (Ascensão et al., 2006; Ascensão et al., 2005; Powers et al.,
1993). Wonders et al. (2008) found that an acute bout of treadmill exercise
significantly reduced lipid peroxidation in animals receiving a 15 mg/kg bolus
injection of DOX. Likewise, a more recent study by Ascensão et al. (2011),
examined the effects of an acute bout of exercise on DOX-treated rats.
Animals in the exercise group performed a 60-minute treadmill exercise bout
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24 hours prior to receiving a DOX injection (20 mg/kg). Results indicated that
exercise provided a cardioprotective response from DOX treatment by
increasing cardiac mitochondrial SOD activity and reducing caspase activity.
An early study by Kanter et al. (1985) was one of the first to report the
effects of chronic aerobic exercise on DOX-induced oxidative stress. The
study examined the effects of a 21-week swim training program on antioxidant
enzymes and DOX-associated cardiotoxicity. The investigators reported that
chronic exercise training led to physiological adaptations eliciting
cardioprotective effects counteracting DOX, which may have been attributed to
the upregulation of antioxidant enzymes. This has been substantiated by
studies examining different modes of exercise and the time course of
treatment. Kavazis et al. (2010) found that a short-term exercise training (10
sessions) prior to a single bolus injection of DOX (20 mg/kg) increased
manganese superoxide dismutase (MnSOD), copper zinc superoxide
dismutase (CuSOD), CAT, and GPX while attenuating DOX-induced 4hydroxynonenal formation. A study by Chicco et al. (2006) examined the
effects of a long-term training program (12 weeks) prior to DOX treatment and
reported a significant decrease in lipid peroxidation. The role of oxidative
stress on intracellular damage has been well-established. The data suggest
that exercise is an effective countermeasure to intracellular damage caused by
oxidative stress. This, in part, could be due to increase myocardial
antioxidants.
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Heat Shock Proteins
One mechanism by which exercise may protect the myocardium is
through the induction of HSPs. The HSPs serve as molecular chaperones
during both protein assembly and membrane translocation. An elevation of
HSPs may play a protective role by preventing the denaturing of regulatory
proteins, stabilizing newly denatured proteins, and protecting against
apoptosis (Powers & Demirel, 2001).
Demirel et al. (1998) conducted a 10-week treadmill training program
with rats and measured HSP72 expression. Exercised animals ran 4 days per
week and up to 90 minutes per day at 75% of maximal oxygen consumption
(VO2max). The investigators reported that exercise training was associated
with a large (450%) increase in HSP72 in the LV. A study conducted by Harris
and Starnes (2001) had animals performing a three-, six-, or nine-week
chronic exercise program. After a week habituation of running on the treadmill
at 6% incline for 10 minutes, the duration of the exercise was gradually
increased to 60 minutes per day for five days a week by the end of week
three. The duration and intensity was maintained throughout the remaining
weeks. Animals in the exercise trained groups produced an 8.5-fold, 10.7-fold,
and 12.3-fold increase in HSP70 in the LV, for three-, six-, and nine-week
training groups, respectively. Similarly, studies have examined cardiac HSP
expression posttraining as a method to attenuate DOX-induced cardiac
dysfunction. A study by Chicco et al. (2006) reported an increase expression
of HSP72 in an exercise group, which attenuated DOX-induced cardiac
dysfunction. Ample evidence has indicated that exercise can elicit altered and
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increased expression of HSPs; however, evidence to support variations of
intensity-related physiological adaptations has yet to be determined (Locke et
al., 1995; Noble et al., 1999). Despite evidence that increased HSP
expression may provide a cardioprotective effect, studies have reported that
this exercise-induced cardioprotection may be mechanistically independent to
the observed increase in HSPs (Kavazis et al., 2010; Taylor, Harris, &
Starnes, 1999).
Myosin Heavy Chain Expression
The DOX treatment has been shown to induce an α-β shift in MHC
isoforms, ultimately resulting in impaired cardiac function. Aerobic exercise
prior to and during DOX treatment has been shown to preserve α-MHC
expression and attenuate DOX-induced cardiac dysfunction (Hydock et al.,
2012). Hydock, Wonders, Schneider, and Hayward (2005) examined the
effects of voluntary wheel running on MHC distribution during six weeks of
DOX treatment. It was concluded that exercise during DOX treatments leads
to a significant increase in the expression of α-MHC when compared to the
SED DOX group. Furthermore, Hydock et al. (2008) examined if exercise
preconditioning would provide a cardioprotective effect against a single bolus
injection of DOX (10 mg/kg) and whether this was associated with altered
MHC expression. Animals performed a progressive treadmill training program
for 10 weeks followed by DOX treatment and what was observed was a
preservation of MHC isoform distribution that could be linked to
cardioprotection. DOX-induced cardiac dysfunction may be influenced by a
noticeable shift in MHC expression from α to β isoforms. Evidence suggests
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that preservation of α-MHC expression may play a mechanistic role in
exercise-induced cardioprotection. Although the percentage of cardiac α-MHC
isoform differs greatly between humans (< 3%) and rats (> 90%), its
expression plays an important role in human cardiac function (Miyata, Minobe,
Bristow, & Leinwand, 2000). A study by Lowes et al. (1997) reported a
downregulation of α-MHC with a corresponding upregulation of β-MHC in
failing ventricular myocardium. The α to β shift is linked to significant
decreases to cardiac contractility (Tardiff et al., 2000).
Doxorubicin Accumulation
The DOX treatment can lead to its accumulation in tissues including
skeletal and cardiac muscle which may explain functional decrements
(Hayward et al., 2013). Recent studies from our laboratory have reported that
exercise, both voluntary wheel running and treadmill training, resulted in
decreased DOX accumulation (Gibson, Quinn, Pfannenstiel, Bashore, et al.,
2013; Jensen et al., 2013). From these studies, it appears as though
preservation of cardiac function may be influenced by a decrease in DOX
accumulation (Jensen et al., 2013).
The accumulation of DOX within cardiomyoctyes may be a result of
multidrug resistance protein (MRP) regulation. MRPs are a part of the
superfamily of ATP binding cassette (ABC) transporters that function as drug
efflux pumps. Multiple types of MRPs have been reported to be expressed in
cardiac tissue, including MRP-1, MRP-2, and MRP-7 (Gibson, Quinn,
Pfannenstiel, Hydock, & Hayward, 2013). Evidence has indicated that
exercise can increase expression of myocardial MRP-1, MRP-2, and MRP-7,
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which can lead to the preservation of cardiac function as a result of decreases
in DOX accumulation (Gibson, Quinn, Pfannenstiel, Bashore, et al., 2013;
Krause et al., 2007).
Resistance Training
The benefits of acute and chronic aerobic exercise on cardiac
dysfunction have received a great deal of attention. Since myocardial tissue
relies heavily on oxidative metabolism, much of the research has focused on
aspects of oxidative metabolism; there is a limited amount of research
investigating the cardioprotective effects of resistance exercise training.
Though limited, some studies have indicated beneficial effects to both
physiological and pathological processes.
The beneficial effects of RT training may be influenced by the
adaptations that occur to the cardiovascular system. Similar to aerobic
training, physiological cardiac hypertrophy can occur with RT. Characteristics
of the cardiac hypertrophy, however, differ between the two due to the type of
circulatory overload that occurs with RT (Pluim, Zwinderman, van der Laarse,
& van der Wall, 2000). Possible adaptations that may occur include increased
interventricular septum and wall thickness, which has led to this type of
hypertrophy being termed concentric cardiac hypertrophy. Concentric cardiac
hypertrophy has been observed in pathological conditions such as
hypertension, which can be linked to systolic and diastolic dysfunction
(Barauna, Rosa, Irigoyen, & de Oliveira, 2007). However, it has been
indicated that the cardiac hypertrophy observed from RT will not lead to
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abnormalities in function but may enhance systolic function (Colan, Sanders, &
Borow, 1987; Levinger, Bronks, Cody, Linton, & Davie, 2005).
Not only can RT influence hypertrophy, it can also provide
cardioprotection against intracellular damage. In order to induce adaptions
that will, in turn, attenuate oxidative stress, an acute bout of exercise must
actually elicit oxidative stress. Studies have reported that an acute bout of a
resistance exercise can cause an increase in ROS as well as can lead to an
attenuation of oxidative damage (Goldfarb, Bloomer, & McKenzie, 2005;
McBride, Kraemer, Triplett-McBride, & Sebastianelli, 1998; Vincent, Vincent,
Braith, Lennon, & Lowenthal, 2002). The above studies do indicate that an
acute bout of resistance exercise can induce oxidative stress as well as serve
as a stimuli, which will attenuate it; however, studies that look specifically at
myocardial oxidative stress are extremely limited. Chicco et al. (2006)
examined the effects of a six-week RT program on cardiac oxidative stress
caused by alcohol consumption. Rats were assigned to one of four groups:
SED, SED plus alcohol treatment, RT, or RT plus alcohol treatment. The
exercise groups trained by standing on their hind limbs while wearing a
weighted vest. Training activity was repeated 30 times per session three days
a week. The load lifted was incrementally increased by 20% of the animal’s
body weight each week. Results of the study indicated that this type of RT
attenuated ethanol-induced cardiac lipid peroxidation. The studies above
indicate that resistance exercise can induce cellular damage, which in turn can
lead to an adaptation whereby the cell is protected against oxidative stress.
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The RT-induced cardioprotection, in the form of improved cardiac
function, has also been observed with other models. A study by Soufi, Saber,
Ghiassie, and Alipour (2011) showed the cardioprotective effects of a 12-week
RT program against ischemia-reperfusion-induced injury in rats. Training was
performed on a squat-training apparatus in which rats would stand on their
hind legs. Through an electrical stimulation of the rat’s tail, hind limbs would
contract, raising a weighted piston that was located above the animals head.
Animals performed four sets of 12 repetitions per day, with a 90-second rest
period between each set, five times per week for 12 weeks. The investigators
noted that the observed significant (p < .05) increases in LVDP indicated that
this type of RT model can provide cardioprotection against myocardial injuries.
This RT-induced improvement in cardiac function has also been observed in
patients with mild and chronic congestive heart failure (Levinger et al., 2005;
Palevo, Keteyian, Kang, & Caputo, 2009). These studies suggest that
resistance exercise training may provide protection against treatments and
conditions that cause myocardial injury.
Summary
Although DOX is limited by a dose-dependent cardiotoxicty, it still
remains one of the most effective antieoplastic agents used to treat a variety
of cancers. Acute and chronic DOX treatments may elicit varying degrees of
cardiac dysfunction including arrhythmias, LV cavity dilation, and chronic heart
failure. Though we continue to learn more about the mechanisms behind the
development of cardiotoxicity, it has been proposed that uncontrolled
generation of ROS plays a key role. Exercise has been shown to mitigate
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DOX-induced cardiotoxicity and preserve cardiac function. This exerciseinduced attenuation is thought to be linked to a variety of positive physiological
adaptations including increased HSP capacity, decreased caspase activity,
preservation of the cardiac MHC isoform distribution, and increased
antioxidant activity. Multiple studies have implemented treadmill or voluntary
wheel running as the modality of exercise intervention, while few researchers
have examined the effects of RT on DOX-associated toxicity. Therefore, the
purpose of this study was to determine the effects of chronic resistance
exercise preconditioning on DOX-induced cardiac dysfunction and DOXinduced oxidative injury.
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CHAPTER III

METHODS

Experimental Design
The exercise modality implemented in this study mimicked resistance
exercise training and consisted of a raised-caged model, which forces animals
to assume an erect bipedal stance while feeding and drinking. Following 12
weeks of training, a bolus 12.5 mg/kg doxorubicin (DOX) injection was
administered 24 hours after trained animals had been placed into nonelevated cages. Control animals received a bolus intraperitoneal injection of
0.9% SAL. Rats were sacrificed five days after DOX treatment, and cardiac
function was analyzed both in vivo and ex vivo. Following ex vivo cardiac
function assessment, the LV was isolated and flash frozen in liquid nitrogen for
biochemical analysis.
Subjects
Ten-week-old male Sprague Dawley rats (N = 48) were randomly
assigned to sedentary (SED) (n = 24) or RT (n = 24) groups in a temperaturecontrolled facility with a 12:12-hour light-dark cycle. Rats were provided
standard rat chow and water ad libitum. All protocols used for the study were
approved by the University of Northern Colorado Institutional Animal Care and
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Use Committee and was in compliance with the Animal Welfare Act guidelines
(see Appendix).
Exercise Training
Animals that were randomly assigned to the RT group were placed in
cages that allow for a progressive elevation of food and water, encouraging
the animals to rise to a bipedal stance each time they eat and drink. Cage
height was raised to specified heights using specially designed plastic spacers
that sat between the standard cage and the standard cage lid. Placement of
the spacers between the cage and the lid raises the food and water to the
desired height. This RT model has been shown to increase hind limb muscle
mass and increased tibial cortical bone (Yao, Jee, Chen, Li, & Frost, 2001).
On day one of the training protocol, cage height was raised from the standard
20.32 cm to a height of 28 cm. Cage height remained at 28 cm for one week.
Following the first week, the height was raised by 2.5 cm. From there, every
third day cages were raised 2.5 cm until they reach the final height of 35.5 cm.
This height was maintained for an additional 10 weeks for a total of 12 weeks
of training. Food and body weight were recorded daily, and adequate water
consumption was confirmed for the first three weeks of training to ensure
animals were able to reach both food and water. Following the first three
weeks of training, animals had their food measured and water monitored three
days per week, and body weight was measured weekly.
At the completion of the 12-week training period, all plastic spacers
were removed so that that all food and water returned to the standard cage
height. This was done to ensure that there were no effects of acute exercise
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on the observed dependent variables. All animals remained in these standard
cages for 24 hours prior to DOX treatment. Following the 24-hour period,
each animal was randomly assigned to one of four groups: SED+SAL (n = 9),
SED+DOX (n = 15), RT+SAL (n = 9), and RT+DOX (n = 15). The SAL groups
received a bolus intraperitoneal 0.9% SAL injection, and the DOX group
received a bolus intraperitoneal 12.5 mg/kg DOX injection.
Various exercise modalities have been used to mimic RT. These
include tower climbing (Notomi et al., 2001), an erected bipedal stance
exercise with a weighted vest (Westerlind et al., 1998), and an erected bipedal
stance whole-body exercise (Yao et al., 2000). Consistent findings have
observed that an exercise modality that mimics RT can cause adaptation to
bone, skeletal muscle, and cardiac muscle (Barauna et al., 2007; Duncan,
Williams, & Lynch, 1998; Notomi et al., 2001). There is no standard or set
protocol for laboratory animal weight-bearing exercise modalities. The range
of total repetitions and total resistance varies greatly between studies.
The RT model has been used by others (Mo et al., 2002; Rosa, Firth,
Blair, Vickers, & Morel, 2011; Yao et al., 2000) and pilot studies in our
laboratory. Recently in our laboratory, the RT model has been associated with
positive functional adaptations in skeletal muscle, which have also been
observed following resistance protocols discussed previously. These data,
along with the pilot study, suggest that the exercise modality may be an
effective model for exercise-induce cardiac adaptations.
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Assessment of Cardiac Function
In Vivo Cardiac Function
In vivo cardiac function was analyzed five days after DOX treatment via
echocardiography. Animals were sedated with ketamine (40 mg/kg,
intraperitoneal), and the anterior and left lateral thoracic regions were shaved.
Transthoracic echocardiography was conducted on the sedated rats using a
General Electric Vivid 7 ultrasound with a 10-MHz introperative transducer
(Tustin, California). Measurements of septal wall thickness during systole and
diastole, posterior wall thickness during systole and diastole, LV end systolic
and diastolic diameter, and FS were acquired by M-mode tracings of the LV
obtained in a short axis view. From an apical view using a pulsed-wave
Doppler, aortic and mitral blood flow echocardiographic images were obtained
providing measurements of maximal flow velocity for both aortic and mitral
valves. All echocardiographic measurements were averaged from three
consecutive cardiac cycles. All M-mode and Doppler measurements were
made in accordance with guidelines established by the American Society of
Echocardiography.
Ex Vivo Cardiac Function
Ex vivo cardiac function was analyzed following echocardiography via
an isolated working-heart model (ADInstruments, Colorado Springs,
Colorado). Each animal was anesthetized using an intraperitoneal injection of
heparinized (500 U) sodium pentobarbital (50 mg/kg). Following an absent tail
pinch reflex, the heart was excised and placed into ice cold Krebs-Henseleit
buffer (in mM: 120 NaCl, 5.9 KCl, 2.5 CaCl2, 1.2 MgCl, 25 NaHCO3, 17
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glucose, and 0.5 ethylenediaminetetraacetic acid [EDTA]) aerated with 95%
O2 – 5% CO2. Hearts were quickly cannulated by the ascending aorta and
subjected to retrograde perfusion until all blood was cleared from the coronary
vasculature. The pulmonary vein was then cannulated, and blood flow was
redirected from the aorta to the left atrium to initiate the working-heart model.
Once stabilized, a microtip catheter pressure transducer (Millar Inc., Houston,
Texas) was placed into the LV via the apex for determination of LV developed
pressure (LVDP), LV maximal rate of ventricular pressure development
(+dP/dt), and LV rate of pressure decline (-dP/dt). Preload was set at 10
cmH2O and was maintained for all subsequent functional measurements.
Afterload was progressively increased every three to five minutes during data
collection from 85 cmH2O, to 100 cmH2O, and to 115 cmH2O. After data were
collected at the three different afterloads, afterload was adjusted to 100
cmH2O, and hearts were paced at 240 beats per minute using electrodes
attached to the cannula. The LV functional data were collected and analyzed
using a PowerLab data acquisition system (ADInstruments). Once data were
collected, hearts were trimmed of connective tissue and fat and weighed. The
LVs were then isolated, flash frozen in liquid N2, and stored at –80°C until
subsequent biochemical analyses.
Biochemical Analysis
Lipid Peroxidation
A commercially available assay kit (Bioxytech MDA-586, Oxis
Research, Foster City, California) was used to measure malondialdehyde +
4˗hydroxyalkenal (MDA + 4-HAE) as an indicator of cellular lipid peroxidation.
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Tissues were homogenized in a radioimmunoprecipitation buffer for the assay.
A 200 µL aliquot of each sample was added to a microcentrifuge tube followed
by 650 µL of N-methyl-2-phenylindole in acetonitrile and briefly vortexed.
Next, 150 µL of methanesulfonic acid was added, vortexed, and incubated at
45°C for 60 minutes. Samples were then centrifuged at 10,000 g for 10
minutes. The resulting supernatant was transferred to a cuvette and
absorbency measured using a spectrophotometer at 586 nm. The MDA + 4HAE was estimated from a standard curve. All samples were assayed in
duplicate, and any samples varying more than 5% were reassessed.
Myosin Heavy Chain Analysis
Sample preparation was adapted from the method of Thomason,
Baldwin, and Herrick (1986). Approximately 100 mg of LV tissue was minced
in a 2 mL glass tissue homogenizer with surgical scissors. A 1:10
weight/volume ratio of homogenization buffer (250 mM sucrose, 100 mM KCl,
5 mM EDTA, and 20 mM Tris-Base, 4°C, pH 6.8) was added to the
homogenizer. The sample was homogenized approximately five minutes
using a ScilogexD160 homogenizer (Rocky Hill, Connecticut). Homogenates
were centrifuged at 1,000 g for 10 minutes at 4°C and pellets collected and
resuspended, with the same volume as the homogenization buffer, in a
washing buffer (175 mM KCl, 0.5% Triton X-100, 2 mM EDTA, and 20 mM
Tris-Base, 4°C, pH 6.8). Samples were centrifuged again at 1,000 g for 10
minutes at 4°C. The pellets were collected, resuspended with the same
volume as the previous washing buffer, and centrifuged at 1,000 g for 10
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minutes at 4°C. The pellets were resuspended in the final resuspension buffer
(150 mM KCl, and 20 mM Tris-Base, pH 7.0) at 1/12 of the previous volume.
Total protein concentration was determined using the Bradford protein
assay method (Bradford, 1976). Samples were then diluted to 2 mg/mL with
the final resuspension buffer. Twenty-five µL of each sample was further
diluted to 0.125 mg/mL with 2x Laemmli sample buffer (20% glycerol, 16% 1M
Tris [pH 6.8], 4% sodium dodecylsulfate [SDS], 1% β-mercaptoethanol, and
0.2% bromophenol blue). To denature the proteins, samples were boiled for
two minutes and then placed on ice for another 10 minutes. Following the 10
minutes on ice, samples were loaded onto polyacrylamide gels.
A SDS polyacrylamide gel electrophoresis was used to determine MHC
isoform expression. The MHC gel composition used the modified method of
Reiser and Kline (1998) from the original method of Talmadge and Roy
(1993). A 0.75 mm Snap-A-Gel cassette (Jule, Inc., Milford, Connecticut) was
used to cast polyacrylamide gels. The gel polymerization of separating gels
(5% of 100% glycerol, 8% acrylamide-N,N'-methylene, 4% acrylamide-bis
[50:1], 0.2 M Tris-Base [pH 8.8], 0.1 M glycine, and 0.4% of 10% SDS) was
initiated by adding 0.05% N,N,N',N'- tetramethylethylenediamine and 0.1%
ammonium persulfate (10%). After initiating the gel polymerization, the
separating gel solution was pipetted into cassettes to approximately 1 cm
below the height of the bottom of comb. N-butonol was then pipetted to the
top of the gel in order to flatten the separating gel during polymerization.
Cassettes were then placed in the refrigerator for at least 60 minutes to allow
the gel to polymerize.
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Following polymerization of the separating gel, n-butanol was removed
and cassettes rinsed five times with milli-pure water. The polymerization of
the stacking gel (5% of 100% glycerol, 4% acrylamide-bis [50:1], 70 mM TrisBase [pH 6.7], 4 mM EDTA and 0.4% of 10% SDS) was initiated by adding
0.05% tetramethylethylenediamine and 0.1% ammonium persulfate (10%).
The stacking gel solution was pipetted to the top of the separating gel and a
10-lane comb was inserted (Jule, Inc.) into the stacking gel. Cassettes were
then placed in the refrigerator for at least 60 minutes to allow the stacking gel
to polymerize.
Following polymerization of the stacking gel, combs were removed.
Cassettes were placed into Novex Sure Lock cells (Invitrogen Corporation,
Carlsbad, California). Cassettes were locked and then the middle chamber
was filled with upper running buffer (0.1 M Tris, 150 mM glycine, and 0.1%
SDS). Next, 7.5 µL of BenchMark™ protein standard (Invitrogen Corporation)
was loaded in the first lane. Following the protein standard, 7 µL of the
samples was loaded in the remaining lanes. Lower running buffer (50 mM
Tris, 75 mM glycine, and 0.05% SDS) was poured into the outside chamber of
the electrophoresis unit.
Electrophoresis was conducted at 100 V, 25 mA for approximately three
hours or until the tracking dye was near the bottom of the gel. The gels were
then stained with Simply Blue safe stain for 60 minutes. Gels were then
placed in distilled water overnight. The following day, gels were removed and
placed between two transparency sheets and scanned. The density of MHC
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protein bands was analyzed using Image J densitometry software (National
Institutes of Health, Bethesda, Maryland).
Statistical Analysis
Data were analyzed and presented using GraphPad Prism statistical
software. All data are expressed as mean ± standard deviation (M ± SD). A
two-way analysis of variance (ANOVA) was used to determine significant
difference due to the main effects (DOX and RT) and interaction. Upon
observation of a significant difference, a Tukey post-hoc pair-wise comparison
was conducted to evaluate any pair-wise comparisons. For all statistical
analysis, significance is set at α = 0.05.
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CHAPTER IV

RESULTS

The purpose of this study was threefold: (a) to examine the effects of
chronic RT prior to the administration of doxorubicin (DOX) on in vivo and ex
vivo cardiac function in male Sprague Dawley rats, (b) to determine if any
cardioprotective effects are a result of a reduction in lipid peroxidation, and (c)
to determine if any cardioprotective effects are a result of a preservation of the
cardiac MHC isoform distribution.
General Observations
General observations are presented in Table 4.1. Six animals died
during the course of this experiment, making the total mortality rate 20% for
DOX treated-animals. Resistance training cut mortality in half, with SED+DOX
having a mortality rate of 27% (4/15); whereas, the mortality rate for RT+DOX
was 13% (2/15). Animals in both SAL groups continued to gain body weight in
the five days following injection; however, these gains were not significant. A
2-way ANOVA on final body weight revealed a drug effect, F(1, 38) = 29.2, p <
0.0001, with the DOX-treated animals’ body weight significantly lower than the
SAL-treated animals. Five days following injection, body weight decreased
14% for both DOX groups, with no statistically significant difference between
DOX groups. A 2˗way ANOVA on absolute heart mass revealed both a drug
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effect, F(1, 38) = 6.757, p = 0.0132, and activity effect, F(1, 38) = 11.33, p =
0.0018. Absolute heart mass was significantly higher in the RT+SAL group
compared to SED+DOX. Relative heart mass also showed a drug effect,
F(1, 38) = 5.448, p = 0.025, and activity effect, F(1, 38) = 18.87, p = 0.0001.
Both RT groups had greater heart mass when compared to SED+SAL.
RT+DOX heart mass relative to body weight was also significantly higher than
SED+DOX.

Table 4.1
Subject Demographics

N

SAL

DOX

Injection
body weight
(g)
M ± SD

Final
body weight
(g)
M ± SD

Heart mass
(g)
M ± SD

Relative heart mass
(%)
M ± SD

SED

9

441 ± 37

446 ± 36

1.5 ± 0.18

0.35 ± 0.02

RT

9

439 ± 57

442 ± 54

1.7 ± 0.17†

0.39 ± 0.03*

SED

11

447 ± 31

386 ± 26

1.4 ± 0.14

0.37 ± 0.03

RT

13

446 ± 23

384 ± 22

1.6 ± 0.13

0.40 ± 0.04* †

Note. Data are represented as M ± SD. SED = sedentary; RT = resistance trained;
SAL = saline placebo; DOX = doxorubicin. p < 0.05.
*p < 0.05 versus SED+SAL.
†p < 0.05 versus SED+DOX.

36
Echocardiography
Cardiac geometry (see Table 4.2) and blood flow velocities (see Table
4.3) were measured by echocardiogram. No statistically significant differences
were seen between the groups for SWd, PWs, PWd, LVDs, and FS. Five
days post injection, a 2-way ANOVA on SWs revealed a drug effect, F(1, 38) =
13.39, p = 0.0008. A post hoc analysis determined that SED+DOX SWs was
significantly thinner (p < 0.05) compared to both SAL groups. A drug effect,
F(1, 38) = 14.45, p = 0.0005, was also observed on LVDd. A post hoc
analysis determined that both SAL groups LVDd was significantly greater (p <
0.05) than RT+DOX. Echocardiography Doppler images were used to analyze
maximum blood flow through the aortic valve (A-Vmax) and mitral valve (MVmax). A 2-way ANOVA on the A-Vmax revealed a drug effect, F(1, 38) =
79.25, p < 0.0001, activity effect, F(1, 38) = 15.03, p = 0.0004, and an
interaction, F(1, 38) = 13.42, p = 0.0008. The M-Vmax also had a drug effect,
F(1, 37) = 82.44, p < 0.0001, activity effect, F(1, 37) = 7.002, p = 0.0119, and
interaction, F(1, 37) = 13.32, p = 0.008. Significant decreases in A-Vmax and
M-Vmax occurred with both DOX groups when compared to both SAL groups.
However, RT+DOX A-Vmax and M-Vmax was significantly faster (p < 0.05)
when compared to SED+DOX.
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Table 4.2
Echocardiogram Derived Cardiac Geometry
SED+SAL

SED+DOX

RT+SAL

RT+DOX

M ± SD

N

M ± SD

N

M ± SD

N

M ± SD

N

SWs (mm)

4.02 ± 0.22*

9

3.02 ± 0.56

11

4.17 ± 0.39*

9

3.79 ± 0.43

13

SWd (mm)

2.25 ± 0.24

9

2.10 ± 0.40

10

2.41 ± 0.28

9

2.34 ± 0.35

13

PWs (mm)

3.79 ± 0.27

9

3.51 ± 0.63

11

3.94 ± 0.25

9

3.63 ± 0.89

13

PWd (mm)

2.49 ± 0.31

9

2.33 ± 0.38

11

2.58 ± 0.30

9

2.35 ± 0.28

13

LVDs (mm)

2.29 ± 0.32

8

2.48 ± 1.02

11

2.24 ± 0.24

9

1.93 ± 0.62

13

LVDd (mm)

5.93 ± 0.29†

9

4.94 ± 1.11

11

5.44 ± 0.57†

9

4.33 ± 1.08

13

FS (%)

61.12 ± 5.21

8

51.06 ± 14.1

11

58.69 ± 5.68

9

58.28 ± 9.22

13

Note. Data are represented as M ± SD. SED = sedentary; RT = resistance
trained; SAL = saline placebo; DOX = doxorubicin; SWs = septal wall
thickness during systole; SWd = septal wall thickness during diastole; PWs =
posterior wall thickness during systole; PWd = posterior wall thickness during
diastole; LVDs = left ventricular end systolic diameter; LVDd = left ventricular
end diastolic diameter; FS = fractional shortening.
*p < 0.05 versus SED+DOX.
†p < 0.05 versus RT+DOX.
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Table 4.3
Echocardiogram Derived Blood Flow Velocity
SED+SAL

SED+DOX

RT+SAL

RT+DOX

M ± SD

N

M ± SD

N

M ± SD

N

M ± SD

N

M-Vmax

98 ± 11*†

8

39 ± 9

11

93 ± 17*†

9

68 ± 10*

13

A-Vmax

74 ± 15*†

9

31 ± 10

11

75 ± 10*†

9

57 ± 10*

13

Note. Data are represented as M ± SD. SED = sedentary; RT = resistance
trained; SAL = saline placebo; DOX = doxorubicin; M-Vmax = maximum blood
flow through mitral valve; A-Vmax = maximum blood flow through aortic valve.
*p < 0.05 versus SED+DOX.
†p < 0.05 versus RT+DOX.

Isolated Perfused Working Heart
Following echocardiographic measurements, the cardiac variables
ESP, EDP, LVDP, +dP/dt, -dP/dt, and heart rate were analyzed using an
isolated working-heart apparatus. Afterload was set at three different heights
(85, 100, and 115 cmH2O) during the analysis. No statistically significant
differences in heart rate and EDP were observed between the four groups at
any of the afterloads. Cardiac function at the three different afterloads is
displayed in Figure 4.1. At an afterload of 85 cmH2O, an interaction was
observed for ESP, LVDP, and +dP/dt. A post hoc analysis revealed that both
SAL groups and RT+DOX had significantly higher (p < 0.05) ESP, LVDP, and
+dP/dt when compared to SED+DOX. Although RT+DOX was significantly
higher than SED+DOX in ESP (34%) and LVDP (37%), RT+DOX ESP and
LVDP were significantly lower than both SAL groups.
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At an afterload of 100 cmH2O, an interaction was observed for ESP,
LVDP, and +dP/dt. A post hoc analysis revealed that both SAL groups and
RT+DOX had significantly higher ESP, LVDP, and +dP/dt when compared to
SED+DOX. The SED+DOX –dP/dt was also significantly less when compared
to SED+SAL. Similar to an afterload of 85 cmH2O, RT+DOX was significantly
higher than SED+DOX in ESP (44%) and LVDP (46%); however, the group
was significantly lower when compared to both SAL groups. The RT+DOX
+dP/dt was also significantly lower when compared to SED+SAL.
At an afterload of 115 cmH2O, an interaction was observed for ESP,
LVDP, and +dP/dt. A post hoc analysis revealed that both SAL groups and
RT+DOX had significantly higher ESP, LVDP, +dP/dt, and –dP/dt when
compared to SED+DOX. Although RT+DOX was significantly higher than
SED+DOX in ESP (44%), LVDP (46%), and +dP/dt (15%), RT+DOX ESP,
LVDP, and +dP/dt were significantly lower when compared to both SAL
groups.
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Figure 4.1. Unpaced ex vivo cardiac function. (A) end systolic pressure, (B) end
diastolic pressure (C) left ventricular developed pressure, (D) maximal rate of
developed pressure, and (E) maximal rate of pressure decline. Values are M ± SD.
SED = sedentary; RT = resistance trained; SAL = saline placebo; DOX = doxorubicin.
Ψ significant differences between SED+SAL and SED+DOX
# significant differences between RT+SAL and SED+DOX
† significant differences between RT+DOX and SED+DOX
* significant differences between SED+SAL and RT+DOX
Ω significant difference between RT+SAL and RT+DOX
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Paced cardiac function at an afterload of 100 cmH2O is displayed in
Figure 4.2. Following the collection of unpaced data, the afterload was placed
at 100 cmH2O and LV pressure was measured at a standardized pace of 240
beats/min. An interaction was observed for ESP, LVDP, +dP/dt, and -dP/dt.
Both SAL groups and RT+DOX had significantly higher ESP, LVDP, +dP/dt,
and –dP/dt when compared to SED+DOX. No significant differences were
seen between RT+DOX and SAL groups for all variables.

Figure 4.2. Paced ex vivo cardiac function. (A) end systolic pressure, (B) left
ventricular developed pressure, (C) maximal rate of developed pressure, and
(D) maximal rate of pressure decline. Values are M ± SD.
*significantly different than SED+DOX.

As afterload increases, the normal physiological response is an
increase in LV pressure. Although not significant, increases (~ 5%) were
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observed for both SAL groups in ESP, LVDP, and +dP/dt as the afterload
increased from 85 cmH2O to 115 cmH2O. Both DOX groups showed little
(< 2%) to no change in ESP, LVDP, +dP/dt, and –dP/dt as the afterload was
increased from 85 cmH2O to 115 cmH2O.
Biochemical Analysis
All data from biochemical analyses are presented in Table 4.4 and
Figures 4.3 and 4.4. To provide an index of oxidative stress in the
myocardium, MDA + 4-HAE levels were analyzed. A 2-way ANOVA on MDA
+ 4-HAE levels revealed a drug effect, F(1, 38) = 20.01, p < 0.0001. A post
hoc analysis was performed to examine group differences. No significant
difference was seen within both DOX-treated and SAL-treated animals,
however RT+DOX MDA + 4-HAE levels were lower than SED+DOX.

Table 4.4
Biochemical Analysis

MDA + 4-HAE (pmol/mg)
β-MHC (%)

SED+SAL

SED+DOX

RT+SAL

RT+DOX

M ± SD

M ± SD

M ± SD

M ± SD

679 ± 94*†

896 ± 194

673 ± 105*†

829 ± 109

9 ± 3*†

36 ± 12

17 ± 8*

25 ± 9*

Note. Data are represented as M ± SD. SED = sedentary; RT = resistance trained; SAL =
saline placebo; DOX = doxorubicin; MDA = malondialdehyde; HAE = hydroxyalkenal; MHC =
myosin heavy chain.
*p < 0.05 versus SED+DOX.
†p < 0.05 versus RT+DOX.
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The MHC isoform distribution was examined to determine if an isoform
shift played a protective role in DOX-induced cardiac dysfunction. A 2-way
ANOVA on percentage of β-MHC revealed a drug effect, F(1, 38) = 39.83, p <
0.001. Additionally, an interaction effect was observed, F(1, 38) = 11.74, p =
0.0015. A post hoc analysis was performed to examine group differences.
SED+DOX observed a significant increase in the percentage of β-MHC
expression when compared to both SAL groups. The RT+DOX relative βMHC expression was significantly higher than SED+SAL but not RT+SAL.
The RT+DOX percentage of β-MHC was significantly lower than SED+DOX,
indicating a preservation of the cardiac MHC isoform distribution as a result of
RT.

Figure 4.3. Myocardial lipid peroxidation in left ventricular homogenates. SED
= sedentary; RT = resistance trained; SAL = saline placebo; DOX =
doxorubicin. Values are M ± SD. MDA = malondialdehyde; HAE =
hydroxyalkenal.
*significantly different than SED+SAL
†significantly different than RT+DOX.
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A.

SED+SAL

SED+DOX

RT+SAL

RT+DOX

B.

α-MHC
β-MHC

Figure 4.4. β-myosin heavy chain expression in left ventricular homogenates.
Panel A is a representative scan, via ImageJ, from each group. Panel B is the
β-myosin heavy chain expression in the left ventricle. SED = sedentary; RT =
resistance trained; SAL = saline placebo; DOX = doxorubicin; MHC = myosin
heavy chain. Values are M ± SD.
*significantly different than SED+DOX.
†significantly different than RT+DOX.
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CHAPTER V

MANUSCRIPT

Introduction
Cancer is one of the leading causes of morbidity and mortality
throughout the world. In 2015 it is estimated that there will be more than 1.6
million new cases of cancer diagnosed in the United States (Siegel, Miller, &
Jemal, 2015). In addition, it is estimated that more than 580,000 people will
succumb to the disease in 2015, thus statistically making cancer the second
most common cause of death in the United States. Increased survival rates
for cancer patients are due, in part, to progressive methods of prevention,
detection, and treatment options available to patients. Increased survival rates
have led to a greater emphasis on improving overall quality of life in cancer
survivors, with a particular focus on reducing or attenuating treatment-related
side effects.
A Food and Drug Administration approved chemotherapeutic agent
successful in the treatment of a variety of cancers is doxorubicin (DOX),
clinically known as Adriamycin®. Clinicians began prescribing DOX to cancer
patients as a chemotherapy treatment in 1974. Since then, it has been used
to treat a variety of malignancies, both solid and hematological (Weiss, 1992).
While substantially effective at treating cancer, the implementation of DOX into
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routine cancer treatment regimens has been limited due to its known
cardiotoxicity. This well-characterized, dose-dependent cardiotoxicity can be
manifested as cardiac dysrhythmias, contractile dysfunction, or even
congestive heart failure (Steinherz, Steinherz, Tan, Heller, & Murphy, 1991).
Studies have indicated that DOX treatment will significantly reduce systolic
and diastolic function in an isolated perfused heart. Mechanistic actions of
DOX that have been reported to induce cardiotoxicity include interference with
deoxyribonucleic acid (DNA) strand separation during replication (Bachur et
al., 1992), induction of apoptosis (Wonders, Hydock, Greufe, Schneider, &
Hayward, 2009), and excess generation of reactive oxygen species (ROS)
(Minotti, Menna, Salvatorelli, Cairo, & Gianni, 2004).
Other studies have examined one of the central mechanisms of DOXinduced cardiotoxicity, oxidative stress, by measuring lipid peroxidation.
These studies have determined that DOX treatment leads to significant
increases in lipid peroxidation, which initiates a cascade of events causing
diminished cardiac function. The increase in lipid peroxidation has been linked
to a change in myosin heavy chain (MHC) isoform distribution (Aragno et al.,
2006). The MHC isoform distribution plays an essential role in cardiac
contractile properties. An alteration in MHC isoform distribution is reported to
cause diminished contractile velocity (Ramamurthy, Hook, Jones, & Larsson,
2001).
Aside from examining ways to prevent, diagnose, and treat cancer,
researchers have diligently investigated interventions aimed at the reduction or
attenuation of burdensome side effects commonly accompanying cancer
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treatment. Purported to counteract many of the transient and chronic effects
associated with cancer treatments, the role of regular exercise in the
prevention and treatment of cancer has been the focus of much clinical
research over the past 15 years.
Studies have suggested that exercise preconditioning may reduce
DOX-induced cardiotoxcity following treatment (Hydock, Lien, Jensen,
Schneider, & Hayward, 2011; Hydock, Lien, Schneider, & Hayward, 2008;
Jensen, Lien, Hydock, Schneider, & Hayward, 2013). However, not fully
understood are the mechanisms involved with the induction of exercisemediated cardioprotection. Exercise-induced cardioprotection against DOX
toxicity may be explained by upregulation of heat shock proteins (HSP)
(Chicco, Schneider, & Hayward, 2005), down-egulation of pro-apoptotic
pathways (Wonders et al., 2009), increased antioxidant enzymes (Ascensão et
al., 2005; Ashrafi, Roshan, & Mahjoub, 2012; Chicco, Hydock, Schneider, &
Hayward, 2006; Kanter, Hamlin, Unverferth, Davis, & Merola, 1985),
decreased lipid peroxidation (Marques-Alexio et al., 2014; Wonders, Hydock,
Schneider, & Hayward, 2008), decreased cardiac DOX accumulation (Jensen
et al., 2013), preservation of MHC composition (Hydock et al., 2011), and/or
increasing the expression of multi-drug resistance protein (Krause et al., 2007;
Parry & Hayward, in press).
Although a substantial amount of research has focused on the effects of
endurance training, little attention has been placed on the effects of resistance
training (RT) on DOX-induced cardiotoxicity. Cancer rehabilitation programs
have begun to incorporate RT due to the fact that this type of training can
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result in significant improvements in muscular strength, aerobic capacity, and
quality of life (Schwartz & Winters-Stone, 2009; Segal et al., 2003; WintersStone et al., 2012). Additionally, RT has been utilized as a rehabilitative
therapy for heart failure, which may accompany DOX treatment, to counteract
damaging peripheral side effects and improve quality of life (Alves, Nunes,
Stefani, & Dal Lago, 2014). To our knowledge, no studies have been
conducted which examine the effects of RT on DOX-induced cardiotoxicity.
Therefore, the purpose of this study was threefold: (a) to examine the effects
of chronic RT prior to the administration of DOX on in vivo and ex vivo cardiac
function in male Sprague Dawley rats, (b) to determine if any cardioprotective
effects are a result of a reduction in lipid peroxidation, and (c) to determine if
any cardioprotective effects are a result of a preservation of the cardiac MHC
isoform distribution.
Methods
Experimental Design
The exercise modality implemented in this study mimicked resistance
exercise training and consisted of a raised-caged model, which forces animals
to assume an erect bipedal stance while feeding and drinking. Following 12
weeks of training, a bolus intraperitoneal 12.5 mg/kg DOX injection was
administered 24 hours after trained animals had been placed into nonelevated cages. Control animals received a bolus intraperitoneal injection of
0.9% saline (SAL). Rats were sacrificed five days after DOX treatment, and
cardiac function was analyzed both in vivo and ex vivo. Following ex vivo
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cardiac function assessment, the left ventricular (LV) was isolated and flash
frozen in liquid nitrogen for biochemical analysis.
Subjects
Ten-week-old male Sprague Dawley rats (N = 48) were randomly
assigned to sedentary (SED) (n = 24) or RT (n = 24) groups in a temperaturecontrolled facility with a 12:12-hour light-dark cycle. Rats were provided
standard rat chow and water ad libitum. All protocols used for the study were
approved by the University of Northern Colorado Institutional Animal Care and
Use Committee and was in compliance with the Animal Welfare Act guidelines
(see Appendix).
Exercise Training
Animals that were randomly assigned to the RT group were placed in
cages that allow for a progressive elevation of food and water, encouraging
the animals to rise to a bipedal stance each time they eat and drink. Cage
height was raised to specified heights using specially designed plastic spacers
that sat between the standard cage and the standard cage lid. Placement of
the spacers between the cage and the lid raises the food and water to the
desired height. This RT model has been shown to increase hind limb muscle
mass and increased tibial cortical bone (Yao, Jee, Chen, Li, & Frost, 2001).
On day one of the training protocol, cage height was raised from the standard
20.32 cm to a height of 28 cm. Cage height remained at 28 cm for one week.
Following the first week, the height was raised by 2.5 cm. From there, every
third day cages were raised 2.5 cm until they reached the final height of 35.5
cm. This height was maintained for an additional 10 weeks for a total of 12
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weeks of training. Food and body weight were recorded daily, and adequate
water consumption was confirmed for the first three weeks of training to
ensure animals were able to reach both food and water. Following the first
three weeks of training, animals had their food measured and water monitored
three days per week, and body weight was measured weekly.
At the completion of the 12-week training period, all plastic spacers
were removed so that that all food and water returned to the standard cage
height. This was done to ensure that there were no effects of acute exercise
on the observed dependent variables. All animals remained in these standard
cages for 24 hours prior to DOX treatment. Following the 24-hour period,
each animal was randomly assigned to one of four groups: SED+SAL (n = 9),
SED+DOX (n = 15), RT+SAL (n = 9), and RT+DOX (n = 15). The SAL groups
received a bolus intraperitoneal 0.9% SAL injection, and the DOX groups
received a bolus intraperitoneal 12.5 mg/kg DOX injection.
Various exercise modalities have been used to mimic RT. These
include tower climbing (Notomi et al., 2001), an erected bipedal stance
exercise with a weighted vest (Westerlind et al., 1998), and an erected bipedal
stance whole-body exercise (Yao et al., 2000). Consistent findings have
observed that an exercise modality that mimics RT can cause adaptation to
bone, skeletal muscle, and cardiac muscle (Barauna, Rosa, Irigoyen, & de
Oliveira, 2007; Duncan, Williams, & Lynch, 1998; Notomi et al., 2001). There
is no standard or set protocol for laboratory animal weight-bearing exercise
modalities. The range of total repetitions and total resistance varies greatly
between studies.
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The RT model has been used by others (Mo et al., 2002; Rosa, Firth,
Blair, Vickers, & Morel, 2011; Yao et al., 2000) and pilot studies in our
laboratory. Recently in our laboratory, the RT model has been associated with
positive functional adaptations in skeletal muscle, which has also been
observed following resistance protocols discussed previously. These data,
along with the pilot study, suggest that the exercise modality may be an
effective model for exercise-induce cardiac adaptations.
Assessment of Cardiac Function
In Vivo Cardiac Function
In vivo cardiac function was analyzed five days after DOX treatment
via echocardiography. Animals were sedated with ketamine (40 mg/kg,
intraperitoneal), and the anterior and left lateral thoracic regions were shaved.
Transthoracic echocardiography was conducted on the sedated rats using a
General Electric Vivid 7 ultrasound with a 10-MHz introperative transducer
(Tustin, California). Measurements of septal wall thickness during systole
(SWs) and septal wall thickness during diastole (SWd), posterior wall
thickness during systole (PWs) and posterior wall thickness during diastole
(PWd), LV end systolic diameter (LVSd) and LV end diastolic diameter
(LVDd), and fractional shortening (FS) were acquired by M-mode tracings of
the LV obtained in a short axis view. From an apical view using a pulsedwave Doppler, aortic and mitral blood flow echocardiographic images were
obtained providing measurements of maximal flow velocity for both aortic and
mitral valves. All echocardiographic measurements were averaged from three
consecutive cardiac cycles. All M-mode and Doppler measurements were
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made in accordance with guidelines established by the American Society of
Echocardiography.
Ex Vivo Cardiac Function
Ex vivo cardiac function was analyzed following echocardiography via
an isolated working-heart model (ADInstruments, Colorado Springs,
Colorado). Each animal was anesthetized using an intraperitoneal injection of
heparinized (500 U) sodium pentobarbital (50 mg/kg). Following an absent tail
pinch reflex, the heart was excised and placed into ice cold Krebs-Henseleit
buffer (in mM: 120 NaCl, 5.9 KCl, 2.5 CaCl2, 1.2 MgCl, 25 NaHCO3, 17
glucose, and 0.5 EDTA [ethylenediaminetetraacetic acid]) aerated with 95%
O2 – 5% CO2. Hearts were quickly cannulated by the ascending aorta and
subjected to retrograde perfusion until all blood was cleared from the coronary
vasculature. The pulmonary vein was then cannulated, and blood flow was
redirected from the aorta to the left atrium to initiate the working-heart model.
Once stabilized, a microtip catheter pressure transducer (Millar Inc., Houston,
Texas) was placed into the LV via the apex for determination of LV developed
pressure (LVDP), LV maximum rate of developed pressure (+dP/dt), and
minimum rate of developed pressure (-dP/dt). Preload was set at 10 cmH2O
and was maintained for all subsequent functional measurements. Afterload
was progressively increased every three to five minutes during data collection
from 85 cmH2O, to 100 cmH2O, and to 115 cmH2O. After data were collected
at the three different afterloads, afterload was adjusted to 100 cmH 2O, and
hearts were paced at 240 beats per minute using electrodes attached to the
cannula. The LV functional data were collected and analyzed using a
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PowerLab data acquisition system (ADInstruments). Once data were
collected, hearts were trimmed of connective tissue and fat and weighed. The
LVs were then isolated, flash frozen in liquid N2, and stored at – 80°C until
subsequent biochemical analyses.
Biochemical Analysis
Lipid Peroxidation
A commercially available assay kit (Bioxytech MDA-586, Oxis
Research, Foster City, California) was used to measure malondialdehyde + 4hydroxyalkenal (MDA + 4-HAE) as an indicator of cellular lipid peroxidation.
Tissues were homogenized in a radioimmunoprecipitation buffer for the assay.
A 200 µL aliquot of each sample was added to a microcentrifuge tube followed
by 650 µL of N-methyl-2-phenylindole in acetonitrile and briefly vortexed.
Next, 150 µL of methanesulfonic acid was added, vortexed, and incubated at
45°C for 60 minutes. Samples were then centrifuged at 10,000 g for 10
minutes. The resulting supernatant was transferred to a cuvette and
absorbency measured using a spectrophotometer at 586 nm. The MDA + 4HAE was estimated from a standard curve. All samples were assayed in
duplicate, and any samples varying more than 5% were reassessed.
Myosin Heavy Chain Analysis
Sample preparation was adapted from the method of Thomason,
Baldwin, and Herrick (1986). Approximately 100 mg of LV tissue was minced
in a 2 mL glass tissue homogenizer with surgical scissors. A 1:10
weight/volume ratio of homogenization buffer (250 mM sucrose, 100 mM KCl,
5 mM EDTA, and 20 mM Tris-Base, 4°C, pH 6.8) was added to the
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homogenizer. The sample was homogenized approximately five minutes
using ScilogexD160 homogenizer (Rocky Hill, Connecticut). Homogenates
were centrifuged at 1,000 g for 10 minutes at 4°C and pellets collected and
resuspended, with the same volume as homogenization buffer, in washing
buffer (175 mM KCl, 0.5% Triton X-100, 2 mM EDTA and 20 mM Tris-Base,
4°C, pH 6.8). Samples were centrifuged again at 1,000g for 10 minutes at
4°C. The pellets were collected, resuspended with the same volume as
previous washing buffer, and centrifuged at 1,000 g for 10 minutes at 4°C.
The pellets were resuspended in the final resuspension buffer (150 mM KCl,
and 20 mM Tris-Base, pH 7.0) at 1/12 of the previous volume.
Total protein concentration was determined using the Bradford protein
assay method (Bradford, 1976). Samples were then diluted to 2 mg/mL with
the final resuspension buffer. Twenty-five µL of each sample was further
diluted to 0.125 mg/mL with 2x Laemmli sample buffer (20% glycerol, 16% 1M
Tris [pH 6.8], 4% sodium dodecylsulfate [SDS], 1% β-mercaptoethanol, and
0.2% bromophenol blue). To denature the proteins, samples were boiled for
two minutes and then placed on ice for another 10 minutes. Following the 10
minutes on ice, samples were loaded onto polyacrylamide gels.
The SDS polyacrylamide gel electrophoresis was used to determine
MHC isoform expression. The MHC gel composition used the modified
method of Reiser and Kline (1998) from the original method of Talmadge and
Roy (1993). A 0.75 mm Snap-A-Gel cassette (Jule, Inc., Milford, Connecticut)
was used to cast polyacrylamide gels. The gel polymerization of separating
gels (5% of 100% glycerol, 8% acrylamide-N,N'-methylene, 4% acrylamide-bis

55
[50:1], 0.2 M Tris-Base [pH 8.8], 0.1 M glycine, and 0.4% of 10% SDS) was
initiated by adding 0.05% N,N,N',N'- tetramethylethylenediamine and 0.1%
ammonium persulfate (10%). After initiating the gel polymerization, the
separating gel solution was pipetted into cassettes to approximately 1 cm
below the height of the bottom of comb. N-butonol was then pipetted to the
top of the gel in order to flatten the separating gel during polymerization.
Cassettes were then placed in the refrigerator for at least 60 minutes to allow
the gel to polymerize.
Following polymerization of the separating gel, n-butanol was removed
and cassettes rinsed five times with milli-pure water. The polymerization of
the stacking gel (5% of 100% glycerol, 4% acrylamide-bis [50:1], 70 mM TrisBase [pH 6.7], 4 mM EDTA and 0.4% of 10% SDS) was initiated by adding
0.05% tetramethylethylenediamine and 0.1% ammonium persulfate (10%).
The stacking gel solution was pipetted to the top of the separating gel and a
10-lane comb was inserted (Jule, Inc.) into the stacking gel. Cassettes were
then placed in the refrigerator for at least 60 minutes to allow the stacking gel
to polymerize.
Following polymerization of the stacking gel, combs were removed.
Cassettes were placed into Novex Sure Lock cells (Invitrogen Corporation,
Carlsbad, California). Cassettes were locked and then the middle chamber
was filled with upper running buffer (0.1 M Tris, 150 mM glycine, and 0.1%
SDS). Next, 7.5 µL of BenchMark™ protein standard (Invitrogen Corporation)
was loaded in the first lane. Following the protein standard, 7 µL of samples
was loaded in the remaining lanes. Lower running buffer (50 mM Tris, 75 mM
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glycine, and 0.05% SDS) was poured into the outside chamber of the
electrophoresis unit.
Electrophoresis was conducted at 100 V, 25 mA for approximately three
hours or until the tracking dye was near the bottom of the gel. The gels were
then stained with Simply Blue safe stain for 60 minutes. Gels were then
placed in distilled water overnight. The following day, gels were removed and
placed between two transparency sheets and scanned. Of the two bands on
the gel, the slower migrating band was the α-MHC isoform and the faster was
the β-MHC isoform. The density of MHC protein bands was analyzed using
ImageJ densitometry software (National Institutes of Health, Bethesda,
Maryland).
To quantify protein bands, the scanned gel was opened in ImageJ and
converted to grayscale. The brightness of the image was adjusted to isolate
the protein bands. Both bands were selected and then plotted to present a
graphical depiction of band intensity. The graphical depiction of band intensity
showed two peaks. The area under the two peaks was then marked off and
selected. After selecting each peak, values for the area under each band
peak appeared in a window labeled “Results.” The first value represented the
α-MHC isoform and the second value represented the β-MHC isoform. Both
values were added together and the percentage of β-MHC was calculated.
Statistical Analysis
Data were analyzed and presented using GraphPad Prism statistical
software. All data are expressed as mean ± standard deviation (M ± SD). A
two-way analysis of variance (ANOVA) was used to determine significant
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difference due to the main effects (DOX and RT) and interaction. Upon
observation of a significant difference, a Tukey post-hoc pair-wise comparison
was conducted to evaluate all pair-wise comparisons, which would identify
differences between groups. For all statistical analysis, significance is set at α
= 0.05.
Results
The purpose of this study was threefold: (a) to examine the effects of
chronic RT prior to the administration of DOX on in vivo and ex vivo cardiac
function in male Sprague Dawley rats, (b) to determine if any cardioprotective
effects are a result of a reduction in lipid peroxidation, and (c) to determine if
any cardioprotective effects are a result of a preservation of the cardiac MHC
isoform distribution.
General Observations
General observations are presented in Table 5.1. Six animals died
during the course of this experiment, making the total mortality rate 20% for
DOX treated-animals. The RT cut mortality in half, with SED+DOX having a
mortality rate of 27% (4/15); whereas, the mortality rate for RT+DOX was 13%
(2/15). Animals in both SAL groups continued to gain body weight in the five
days following injection; however, these gains were not significant. A 2-way
ANOVA on final body weight revealed a drug effect, F(1, 38) = 29.2, p <
0.0001, with DOX-treated animals body weight significantly lower than SALtreated animals. Five days following injection, body weight decreased 14% for
both DOX groups, with no statistically significant difference between DOX
groups. A 2-way ANOVA on absolute heart mass revealed both a drug effect,
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F(1,38) = 6.757, p = 0.0132, and activity effect, F(1, 38) = 11.33, p = 0.0018.
Absolute heart mass was significantly higher in the RT+SAL group compared
to SED+DOX. Relative heart mass also showed a drug effect,
F(1, 38) = 5.448, p = 0.025, and activity effect, F(1, 38) = 18.87, p = 0.0001.
Both RT groups had greater heart mass when compared to SED+SAL. The
RT+DOX heart mass relative to body weight was also significantly higher than
SED+DOX.

Table 5.1
Subject Demographics

N

SAL

DOX

Injection
body weight
(g)
M ± SD

Final
body weight
(g)
M ± SD

Heart mass
(g)
M ± SD

Relative heart mass
(%)
M ± SD

SED

9

441 ± 37

446 ± 36

1.5 ± 0.18

0.35 ± 0.02

RT

9

439 ± 57

442 ± 54

1.7 ± 0.17†

0.39 ± 0.03*

SED

11

447 ± 31

386 ± 26

1.4 ± 0.14

0.37 ± 0.03

RT

13

446 ± 23

384 ± 22

1.6 ± 0.13

0.40 ± 0.04* †

Note. Data are represented as M ± SD. SED = sedentary; RT = resistance
trained; SAL = saline placebo; DOX = doxorubicin. p < 0.05.
*p < 0.05 versus SED+SAL.
†p < 0.05 versus SED+DOX.
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Echocardiography
Cardiac geometry (see Table 5.2) and blood flow velocities (see Table
5.3) were measured by echocardiogram. No statistically significant differences
were seen between groups for SWd, PWs, PWd, LVDs, and FS. Five days
post injection, a 2-way ANOVA on SWs revealed a drug effect,
F(1, 38) = 13.39, p = 0.0008. A post hoc analysis determined that SED+DOX
SWs was significantly thinner (p < 0.05) compared to both SED groups. A
drug effect, F(1, 38) = 14.45, p = 0.0005, was also observed on LVDd. A post
hoc analysis determined that SED+SAL LVDd was significantly greater (p <
0.05) than RT+DOX. Echocardiography Doppler images were used to analyze
maximum blood flow through the aortic (A-Vmax) and mitral valves (M-Vmax).
A 2-way ANOVA on A-Vmax revealed a drug effect, F(1, 38) = 79.25, p <
0.0001, activity effect, F(1, 38) = 15.03, p = 0.0004, and interaction, F(1, 38) =
13.42, p = 0.0008. The M-Vmax also had a drug effect, F(1, 37) = 82.44, p <
0.0001, activity effect, F(1, 37) = 7.002, p = 0.0119, and interaction, F(1, 37) =
13.32, p = 0.008. Significant decreases in A-Vmax and M-Vmax occurred with
both DOX groups when compared to both SAL groups. However, RT+DOX AVmax and M-Vmax was significantly faster (p < 0.05) when compared to
SED+DOX.
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Table 5.2
Echocardiogram Derived Cardiac Geometry
SED+SAL

SED+DOX

RT+SAL

RT+DOX

M ± SD

N

M ± SD

N

M ± SD

N

M ± SD

N

SWs (mm)

4.02 ± 0.22*

9

3.02 ± 0.56

11

4.17 ± 0.39*

9

3.79 ± 0.43

13

SWd (mm)

2.25 ± 0.24

9

2.10 ± 0.40

10

2.41 ± 0.28

9

2.34 ± 0.35

13

PWs (mm)

3.79 ± 0.27

9

3.51 ± 0.63

11

3.94 ± 0.25

9

3.63 ± 0.89

13

PWd (mm)

2.49 ± 0.31

9

2.33 ± 0.38

11

2.58 ± 0.30

9

2.35 ± 0.28

13

LVDs (mm)

2.29 ± 0.32

8

2.48 ± 1.02

11

2.24 ± 0.24

9

1.93 ± 0.62

13

LVDd (mm)

5.93 ± 0.29†

9

4.94 ± 1.11

11

5.44 ± 0.57†

9

4.33 ± 1.08

13

FS (%)

61.12 ± 5.21

8

51.06 ± 14.1

11

58.69 ± 5.68

9

58.28 ± 9.22

13

Note. Data are represented as M ± SD. SED = sedentary; RT = resistance
trained; SAL = saline placebo; DOX = doxorubicin; SWs = septal wall
thickness during systole; SWd = septal wall thickness during diastole; PWs =
posterior wall thickness during systole; PWd = posterior wall thickness during
diastole; LVDs = left ventricular end systolic diameter; LVDd = left ventricular
end diastolic diameter; FS = fractional shortening.
*p < 0.05 versus SED+DOX.
†p < 0.05 versus RT+DOX.
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Table 5.3
Echocardiogram Derived Blood Flow Velocity
SED+SAL

SED+DOX

RT+SAL

RT+DOX

M ± SD

N

M ± SD

N

M ± SD

N

M ± SD

N

M-Vmax

98 ± 11*†

8

39 ± 9

11

93 ± 17*†

9

68 ± 10*

13

A-V max

74 ± 15*†

9

31 ± 10

11

75 ± 10*†

9

57 ± 10*

13

Note. Data are represented as M ± SD. SED = sedentary; RT = resistance
trained; SAL = saline placebo; DOX = doxorubicin; M-Vmax = maximum blood
flow through mitral valve; A-Vmax = maximum blood flow through aortic valve.
*p < 0.05 versus SED+DOX.
†p < 0.05 versus RT+DOX.

Isolated Perfused Working Heart
Following echocardiographic measurements, the cardiac variables
ESP, EDP, LVDP, +dP/dt, -dP/dt, and heart rate were analyzed using an
isolated working-heart apparatus. Afterload was set at three different heights
(85, 100, 115 cmH2O) during the analysis. No statistically significant
differences in heart rate and EDP were observed between the four groups at
any of the afterloads. Cardiac function at the three different afterloads is
displayed in Figure 5.1. At an afterload of 85 cmH2O, an interaction was
observed for ESP, LVDP, and +dP/dt. A post hoc analysis revealed that both
SAL groups and RT+DOX had significantly higher (p < 0.05) ESP, LVDP, and
+dP/dt when compared to SED+DOX. Although RT+DOX was significantly
higher than SED+DOX in ESP (34%) and LVDP (37%), RT+DOX ESP and
LVDP were significantly lower than both SAL groups.
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Figure 5.1. Unpaced ex vivo cardiac function. (A) end systolic pressure, (B) end
diastolic pressure, (C) left ventricular developed pressure, (D) maximal rate of
developed pressure, and (E) maximal rate of pressure decline. Values are M ± SD.
Ψ significant differences between SED+SAL and SED+DOX
# significant differences between RT+SAL and SED+DOX
† significant differences between RT+DOX and SED+DOX
* significant differences between SED+SAL and RT+DOX
Ω significant difference between RT+SAL and RT+DOX
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At an afterload of 100 cmH2O, an interaction was observed for ESP,
LVDP, and +dP/dt. A post hoc analysis revealed that both SAL groups and
RT+DOX had significantly higher ESP, LVDP, and +dP/dt when compared to
SED+DOX. The SED+DOX –dP/dt was also significantly less when compared
to SED+SAL. Similar to an afterload of 85 cmH2O, RT+DOX was significantly
higher than SED+DOX in ESP (44%) and LVDP (46%); however, the group
was significantly lower when compared to both SAL groups. The RT+DOX
+dP/dt was also significantly lower when compared to SED+SAL.
At an afterload of 115 cmH2O, an interaction was observed for ESP,
LVDP, and +dP/dt. A post hoc analysis revealed that both SAL groups and
RT+DOX had significantly higher ESP, LVDP, +dP/dt, and –dP/dt when
compared to SED+DOX. Although RT+DOX was significantly higher than
SED+DOX in ESP (44%), LVDP (46%), and +dP/dt (15%), RT+DOX ESP,
LVDP, and +dP/dt were significantly lower when compared to both SAL
groups.
Paced cardiac function at an afterload of 100 cmH2O is displayed in
Figure 5.2. Following the collection of unpaced data, the afterload was placed
at 100 cmH2O and LV pressure was measured at a standardized pace of 240
beats/min. An interaction was observed for ESP, LVDP, +dP/dt, and -dP/dt.
Both SAL groups and RT+DOX had significantly higher ESP, LVDP, +dP/dt,
and –dP/dt when compared to SED+DOX. No significant differences were
seen between RT+DOX and SAL groups for all variables.
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Figure 5.2. Paced ex vivo cardiac function. (A) end systolic pressure, (B) left
ventricular developed pressure, (C) maximal rate of developed pressure, and
(D) maximal rate of pressure decline. Values are M ± SD.
*significantly different than SED+DOX.

As afterload increases, the normal physiological response is an
increase in LV pressure. Although not significant, increases (~ 5%) were
observed for both SAL groups in ESP, LVDP, and +dP/dt as the afterload
increased from 85 cmH2O to 115 cmH2O. Both DOX groups showed little
(< 2%) to no change in ESP, LVDP, +dP/dt, and –dP/dt as the afterload was
increased from 85 cmH2O to 115 cmH2O.
Biochemical Analysis
All data from biochemical analyses are presented in Table 5.4 and in
Figures 5.3 and 5.4. To provide an index of oxidative stress-induced damage
in the myocardium, MDA + 4-HAE levels were analyzed. A 2-way ANOVA on
MDA + 4-HAE levels revealed a drug effect, F(1, 38) = 20.01, p < 0.0001. A
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post hoc analysis was performed to examine group differences. No significant
difference was seen within both DOX-treated and SAL-treated animals;
however, RT+DOX MDA + 4-HAE levels were lower than SED+DOX.
The MHC isoform distribution was examined to determine if an isoform
shift played a protective role in DOX-induced cardiac dysfunction. A 2-way
ANOVA on percentage of β-MHC revealed a drug effect, F(1, 38) = 39.83,
p < 0.001. Additionally, an interaction effect was observed, F(1, 38) = 11.74,
p = 0.0015. A post hoc analysis was performed to examine group differences.
The SED+DOX observed a significant increase in the percentage of β-MHC
expression when compared to both SAL groups. The RT+DOX relative βMHC expression was significantly higher than SED+SAL but not RT+SAL.
The RT+DOX percentage of β-MHC was significantly lower than SED+DOX,
indicating a preservation of the cardiac MHC isoform distribution as a result of
RT.

Table 5.4
Biochemical Analysis

MDA + 4-HAE (pmol/mg)
β-MHC (%)

SED+SAL

SED+DOX

RT+SAL

RT+DOX

M ± SD

M ± SD

M ± SD

M ± SD

679 ± 94*†

896 ± 194

673 ± 105*†

829 ± 109

9 ± 3*†

36 ± 12

17 ± 8*

25 ± 9*

Note. Data are represented as M ± SD. SED = sedentary; RT = resistance trained; SAL =
saline placebo; DOX = doxorubicin; MDA = malondialdehyde; HAE = hydroxyalkenal; MHC =
myosin heavy chain.
*p < 0.05 versus SED+DOX.
†p < 0.05 versus RT+DOX.
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Figure 5.3. Myocardial lipid peroxidation in left ventricular homogenates.
Values are M ± SD. MDA + 4-HAE = malondialdehyde + 4-hydroxyalkenal.
*significantly different than SED+SAL.
†significantly different than RT+SAL
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A.

SED+SAL

SED+DOX

RT+SAL

RT+DOX

B.

α-MHC
β-MHC

Figure 5.4. β-myosin heavy chain expression in left ventricular homogenates.
Panel A is a representative scan, via ImageJ, from each group. Panel B is the
β-myosin heavy chain expression in the left ventricle. Values are M ± SD.
*significantly different than SED+DOX.
†significantly different than RT+DOX.

Discussion
With increased survival rates for cancer patients, it has become
imperative to examine ways of reducing or attenuating cancer treatmentrelated side effects. The chemotherapeutic agent DOX is one of the most
effective chemotherapeutic agents ever developed; however, its
implementation is limited due to its dose-dependent cardiotoxicity. Extensive
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research has indicated that various types of exercise modalities can attenuate
DOX-induced cardiotoxicity (Hydock et al., 2012; Hydock et al., 2008).
Currently, cancer rehabilitation programs have begun to incorporate RT due to
the fact that this type of training can result in significant improvements in
muscular strength, aerobic capacity, and quality of life (Schwartz & WintersStone, 2009; Segal et al., 2003; Winters-Stone et al., 2012). The primary
purpose of this study was to determine if chronic RT could attenuate the
cardiac dysfunction induced by subsequent DOX treatment. In addition, the
effect of DOX and exercise training on cardiac lipid peroxidation and relative
MHC isoform distribution was examined to provide a potential explanation for
any observed changes in cardiac function. Results indicate that DOX
treatment caused cardiac dysfunction five days after its administration, prior
chronic RT significantly attenuated this dysfunction, and the protective effects
of this exercise modality were associated with a preservation of the MHC
isoform distribution.
Doxorubicin-Induced Cardiac Dysfunction
The DOX treatment regimen used in the present study resulted in a
significant impairment of cardiac function within five days of exposure, which is
in agreement with previous investigations that examined cardiac function five
days post DOX treatment (Hydock et al., 2011; Wonders et al., 2008). These
signs include significant reductions in mitral and aortic blood flow velocities as
well as diminished systolic and diastolic function. However, the DOX-induced
alterations observed were significantly less in the RT+DOX group, indicating a
cardioprotective effect of RT against DOX treatment.
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Measuring ESP, LVDP, and +dP/dt can assess systolic function. In
agreement with previous studies, DOX treatment led to significant decreases
in systolic function ( Chicco et al., 2006; Hydock et al., 2011). Several
mechanisms have been suggested to explain the depression of LV systolic
function that occurs following DOX treatment including cardiomyocyte
apoptosis (Childs, Phaneuf, Dirks, Phillips, & Leeuwenburgh, 2002), impaired
Ca2+ handling (Asayama et al., 1995; Boucek, Dodd, Atkinson, Oquist, &
Olson., 1997), and deleterious MHC shifts (Hydock et al., 2011).
In the present study DOX-treated groups showed diminished diastolic
function. Significant differences were not observed in EDP between the four
groups; however, an increase in afterload did affect diastolic function in the
form of diminished –dP/dt for SED+DOX. Although not significant, when
increasing the afterload from 100 cmH2O to 115 cmH2O, SED+DOX –dP/dt
decreased by 6%. This indicates that at higher afterloads, myocardial
relaxation was impaired. Such an observation could have important
ramifications for untrained cancer survivors who engage in infrequent
exercise. Exposure to moderately elevated afterload-type activities such as
high-intensity aerobic or resistance exercise may impair diastolic function
during the activity. Several mechanisms could be involved in the impaired
relaxation. Impairment may have been caused by diminished Ca2+ uptake via
sarcoendoplasmic reticulum ATPase 2 (SERCA2) as well as a decrease
SERCA2 mRNA expression, which have been observed in previous studies
(Arai et al., 2000; Hydock et al., 2011; Zhang et al., 2012). Although the
mechanisms are not fully understood, previous studies have suggested that

70
SERCA2 impairment could be a result of DOX-induced oxidative stress (Harris
& Doroshow, 1985), which was in fact observed in the current study.
Doxorubicin-Induced Cardiotoxicity
Possible mechanistic actions that could be responsible for DOXinduced cardiac dysfunction include induction of apoptosis, excess generation
of ROS, and unfavorable MHC shifts. One purpose of the current study was to
examine oxidative stress, as measured by MDA + 4-HAE, following DOX
treatment. DOX-treated groups showed a significant increase in oxidative
stress compared to SAL, which is in agreement with previous studies (Chicco
et al., 2006; Wonders et al., 2008). The myocardium is highly aerobic;
therefore, it requires a constant supply of adenosine triphosphate ATP by
oxidative phosphorylation. When DOX is administered it can lead to excess
generation of ROS, mainly due to an increase in redox cycling at complex I in
the electron transport chain (Marcillat, Zhang, & Davies, 1989). As a result
there becomes an imbalance between the antioxidant and pro-oxidant forces
within and outside the cell, which is referred to as oxidative stress. Increased
oxidative stress may lead to a rise in intracellular Ca2+ due to impaired
ryanodine receptor and SERCA2 function (Kim et al., 2006). Furthermore, this
altered Ca2+ homeostasis creates a cascade of events that can induce
apoptosis (Sokolove & Shinaberry, 1988).
Another purpose of the study was to determine if unfavorable shifts in
the MHC isoform distribution occurred following DOX treatment. The DOXtreated animals showed a significant increase in the relative expression of the
β-MHC isoform and a significant decrease in the relative expression of the α-
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MHC isoform. As stated previous, DOX administration can lead to oxidative
stress. This increased oxidative stress may also lead to an increased
expression of β-MHC (Aragno et al., 2006). The expression of both α-MHC
and β-MHC plays an imperative role in cardiac function (Miyata, Minobe,
Bristow, & Leinwand, 2000). Cardiac α-MHC is the primary isoform in rat
hearts (> 90%) and is associated with a greater contraction velocity and higher
ATPase activity (Krenz et al., 2003). Studies have indicated that DOX
treatment can alter MHC distribution causing decreased expression of the αMHC isoform corresponding to an increase expression of the β-MHC isoform.
This α to β shift significantly decreases cardiac contractility (Tardiff et al.,
2000). In the present study, the cardiac dysfunction observed five days
following DOX treatment might be a result of increased oxidative stress and
altered MHC isoform distribution.
Exercise-Induced Cardioprotection
Despite the plethora of studies observing exercise-induced
cardioprotection prior to DOX treatment, no studies have examined if RT prior
to DOX treatment provides a cardioprotective effect. The RT model used in
the current study protected against DOX-induced septal wall thinning, LV
mass reduction, mitral and aortic blood flow decrements, and cardiac
dysfunction.
From available evidence, it appears that multiple mechanisms may be
simultaneously involved with the protective effects of chronic exercise against
DOX-induced cardiotoxicity including, reduced DOX accumulation within the
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cardiomyocyte (Jensen et al., 2013), attenuating unfavorable shifts in MHC
(Hydock et al., 2011), and decreased oxidative stress (Chicco et al., 2005).
Since it has been proposed that the primary mechanism of DOXinduced cardiotoxicity involves increased oxidative stress, a purpose of the
current study was to examine if the RT model used would attenuate DOXinduced oxidative stress. Contrary to the current study, Chicco et al. (2006)
observed an attenuation of ethanol-induced cardiac lipid peroxidation following
six weeks of RT. The difference in results between the two studies may be
due to the intensity of the exercise movement or differing degrees of oxidative
stress provided by DOX versus ethanol. In the previous study, animals
performed exercise movements where the load lifted was started at 20% body
weight and increased by 20% each week (Chicco et al., 2006), as compared to
the current study in which animals exercised at a lower intensity with no
external load. However, the results of the current study are in agreement with
a previous study in which low intensity exercise did not attenuate DOXinduced oxidative stress although there was a preservation of cardiac function
(Chicco et al., 2006).
Another purpose of the study was to determine if cardioprotection is the
result of preservation in relative MHC distribution. Expression of the α-MHC
isoform has been shown to increase following various types of exercise
(Iemitsu et al., 2004; Jin et al., 2000). A possible mechanism involved in this
increased expression of the α-MHC isoform may be an upregulation of
myocardial thyroid hormone receptors. A study by Iemitsu et al. (2004)
detected significant increases in myocardial thyroid hormone receptors α1,
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correlating to an increase in α-MHC isoform expression following eight weeks
of exercise. In the current study, RT+DOX observed significantly less
alteration in MHC isoform distribution compared to SED+DOX, indicating an
exercise effect. This is in agreement with a previous study indicating that
exercise preconditioning preserved MHC isoform distribution following DOX
treatment (Hydock et al., 2011). This suggests that the cardioprotection
observed in this study may be a result of preservation of the MHC isoform
distribution.
Although many studies observe consistent exercise-induced cardiac
adaptations, characteristics of these adaptations differ. Endurance training
results in eccentric hypertrophy that can lead to enlargement of the LV
chamber and increased LV dimensions. The RT results in concentric
hypertrophy, leading to a thickening of the LV wall and greater contractile
force. This is due to the type of circulatory overload that occurs with RT
(Pluim, Zwinderman, van der Laarse, & van der Wall, 2000). The present
study using a RT model clearly demonstrated exercise-induced
cardioprotection, similar to what has been seen with endurance training.
However, the mechanisms surrounding the cardioprotection may differ. A
central theme of endurance training attenuation of DOX-induced cardiotoxicity
is significant decreases in oxidative stress. This was not observed in the
present study. This suggests that alternative mechanisms may be involved
with MHC isoform distribution as it relates to RT-induced cardioprotection.
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Summary
This is the first study to provide evidence suggesting that RT may
preserve cardiac function and prevent deleterious MHC shifts following DOX
treatment. In the current study, DOX treatment resulted in impaired cardiac
function, increased lipid peroxidation, and unfavorable shifts in the cardiac
MHC isoform distribution. However, 12 weeks of RT preconditioning resulted
in a preservation of cardiac function. The cardioprotective effects of exercise
were associated with a preservation of the cardiac MHC isoform distribution.
These findings suggest that chronic RT may be a beneficial counter
measurement to DOX-induced cardiotoxicity. Incorporating resistance training
into a rehabilitation program may influene an imporved quality of life for cancer
survivors.
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